Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer
L Seymour, WR Bezwoda - Breast cancer research and treatment, 1994 - Springer
L Seymour, WR Bezwoda
Breast cancer research and treatment, 1994•SpringerPrevious studies suggest a prognostic role for PDGF in patients with breast cancer, with
patients with high plasma PDGF levels or positive response to therapy. We have examined a
further 58 patients with advanced breast cancer for the presence of tissue PDGF
immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly
significant shorter survival (p= 0.002) than patients with no immunostaining. In addition
PDGF positive patients treated with combination chemotherapy had a significantly lower …
patients with high plasma PDGF levels or positive response to therapy. We have examined a
further 58 patients with advanced breast cancer for the presence of tissue PDGF
immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly
significant shorter survival (p= 0.002) than patients with no immunostaining. In addition
PDGF positive patients treated with combination chemotherapy had a significantly lower …
Abstract
Previous studies suggest a prognostic role for PDGF in patients with breast cancer, with patients with high plasma PDGF levels or positive response to therapy. We have examined a further 58 patients with advanced breast cancer for the presence of tissue PDGF immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly significant shorter survival (p = 0.002) than patients with no immunostaining. In addition PDGF positive patients treated with combination chemotherapy had a significantly lower response rate (p = 0.05) than PDGF negative patients. These results confirm our previous findings that PDGF may be an important indicator of shortened survival and treatment failure in patients with advanced breast cancer.
Springer